Scale-Up and Manufacturing of Regenerative Medicine
Add bookmark
When introducing a regenerative medicine cell based product to a commercial setting, there are a number of things to take into consideration to ensure a commercially viable and safe product for patient use. In this podcast, William Fodor, Director of Translational Sciences, Cell Therapy Group, gives some great insights into the commercial manufacturing scale-up process of cell therapies.
[inlinead]
Have Your Say
Rate this feature and give us your feedback in the comments section below
Tags:
William Fodor
Cell Therapy Group
regenerative medicine
cell therapy
translational sciences
cell therapies
commercialization of regenerative medicine
